Bionano Genomics Q3 2026 gross margin rises to 48%; revenue climbs 12% to $8.3 million

• Bionano Genomics’ third-quarter 2026 revenue rose 12% year over year to $8.3 million; consumables revenue climbed 24% to $4.7 million.
• Gross margin improved to 48%, while operating expenses fell 12% to $10.5 million.
• Bionano Laboratories announced reimbursement milestones and state-level approvals for optical genome mapping tests offered by third parties.
• Full-year 2026 revenue guidance remained at $31 million to $33 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bionano Genomics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001411690-26-000058), on November 10, 2026, and is solely responsible for the information contained therein.